Dr. Shukui Qin is a leading authority in oncology in China, with a distinguished career dedicated to the clinical management and research of hepatobiliary and pancreatic malignancies. As a consultation expert for the Central Health Care Committee and a recipient of the State Council’s Special Government Allowance, he has made significant contributions to establishing standardized diagnostic and therapeutic systems for hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, and other gastrointestinal tumors. He is widely recognized both nationally and internationally for his expertise and leadership in cancer medicine.
Dr. Qin has played a pivotal role in clinical oncology research, having led or participated in more than 350 international and domestic clinical trials of anticancer agents. Among these, he has served as the Leading Principal Investigator (Leading PI) for over 200 national and international studies—positioning him as a key driving force behind the development and approval of innovative therapies in the hepatobiliary and pancreatic cancer fields. His research has been extensively published in top-tier medical journals, including Lancet, NEJM, JAMA, Nature, Science, and JCO. With exceptional scientific rigor, extensive clinical experience, and strategic insight into the development of innovative cancer therapies, Dr. Qin continues to advance China’s oncology discipline toward global excellence, earning profound respect from peers and the deep trust of patients.
